Crestor (Rosuvastatin) in Hispanic and Latino Patients: Documented Efficacy Gaps Explained

Does Rosuvastatin Work Differently in Hispanic and Latino Patients?

Rosuvastatin produces meaningful LDL reductions in Hispanic and Latino patients, but the clinical picture is more complicated than a simple yes-or-no. Documented differences span pharmacogenomics, metabolic risk phenotype, diabetes signal magnitude, and baseline lipid patterns that are more common in this population. Understanding each layer helps clinicians personalize therapy rather than applying a one-size dosing strategy.

The Short Answer on LDL Efficacy

In the JUPITER trial (N=17,802), rosuvastatin 20 mg reduced LDL-C by 50% overall compared with placebo 1. The Hispanic and Latino subgroup (approximately 1,600 participants) showed a broadly similar relative risk reduction for the primary composite cardiovascular endpoint, roughly 44% versus placebo, consistent with the full-cohort finding of 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) 1. So the drug works. The nuance is in who responds how much, at what dose, and with what adverse-effect burden.

Why "Similar Relative Risk Reduction" Is Not the Whole Story

A similar relative risk reduction still leaves room for meaningful absolute-risk differences. Hispanic adults in the United States carry a metabolic syndrome prevalence of approximately 36%, compared with 33% in non-Hispanic White adults, per CDC NHANES surveillance 2. Higher baseline triglycerides and lower HDL cholesterol, both hallmarks of metabolic syndrome, directly influence the lipid milieu in which rosuvastatin operates. Patients with severe hypertriglyceridemia may see blunted percent LDL reduction because a larger fraction of LDL particles are small and dense, less amenable to receptor-mediated clearance. 3

Pharmacogenomics: The Genes That Shape Rosuvastatin Exposure in Hispanic Patients

Pharmacogenomics is the clearest source of documented between-group variability for rosuvastatin. Two transporters, SLCO1B1 and ABCG2, drive most of the clinically relevant pharmacokinetic differences. CYP enzymes matter far less for rosuvastatin than for lipophilic statins like simvastatin or atorvastatin.

SLCO1B1 and Hepatic Uptake

SLCO1B1 encodes OATP1B1, the hepatic uptake transporter responsible for moving rosuvastatin from portal blood into hepatocytes, where it exerts its LDL-lowering effect. The c.521T>C variant (rs4149056) reduces transporter activity, raising plasma rosuvastatin concentrations and simultaneously reducing hepatic drug delivery. The PharmGKB database lists SLCO1B1 as a "Level 1A" pharmacogenomic association for rosuvastatin, its highest evidence tier 4. Carriers of the c.521C allele show area-under-the-curve (AUC) increases of 65 to 117% for rosuvastatin depending on the study 5. Allele frequency data from the 1000 Genomes Project places the c.521C allele at approximately 14 to 18% in individuals of admixed American (AMR) ancestry, the proxy population most comparable to U.S. Hispanic/Latino groups 6. This frequency is lower than in East Asian populations (where it drives the FDA's Asian-ancestry dose recommendation) but higher than in non-Hispanic White cohorts at roughly 10 to 12%.

ABCG2 and Intestinal/Renal Efflux

ABCG2 encodes BCRP, an efflux transporter expressed in the intestine, liver, and kidney. The c.421C>A variant (rs2231142) reduces efflux activity, increasing rosuvastatin systemic AUC by approximately 72% in homozygous A/A carriers per a pharmacokinetic study published in Clinical Pharmacology and Therapeutics 7. PharmGKB again assigns Level 1A evidence to ABCG2 for rosuvastatin 4. The c.421A allele frequency in AMR populations sits near 6 to 9%, lower than East Asian populations (~30%) but not negligible. Patients carrying both an SLCO1B1 c.521C allele and an ABCG2 c.421A allele could experience substantially amplified drug exposure, raising myopathy risk at standard doses.

CYP2C9: Minimal Direct Impact

Unlike simvastatin, rosuvastatin is not meaningfully metabolized by CYP3A4. CYP2C9 performs minor oxidative metabolism of rosuvastatin to N-desmethyl rosuvastatin, but this pathway accounts for less than 10% of total clearance 8. CYP2C9 poor metabolizer status, which reaches approximately 2 to 3% prevalence in Hispanic populations, therefore produces only a modest pharmacokinetic effect on rosuvastatin specifically. CYP2C9 matters far more for warfarin or phenytoin co-prescriptions in the same patient.

Metabolic Syndrome, Diabetes Risk, and the Rosuvastatin Conversation

Hispanic and Latino patients present a specific clinical tension: they need cardiovascular risk reduction and statins deliver it, but they also carry elevated baseline type 2 diabetes risk that the statin itself may modestly worsen.

Baseline Diabetes Prevalence and Risk

The prevalence of diagnosed diabetes in U.S. Hispanic adults is 12.5% versus 7.5% in non-Hispanic White adults, per CDC National Diabetes Statistics Report data 9. An additional estimated 14% of Hispanic adults have prediabetes. This background load of insulin resistance means that Hispanic patients starting rosuvastatin already sit closer to the glycemic threshold beyond which statin-associated diabetes becomes a clinical event.

JUPITER's Diabetes Signal

In JUPITER, new-onset diabetes occurred in 3.0% of rosuvastatin-assigned participants versus 2.4% of placebo participants, yielding a hazard ratio of 1.27 (95% CI 1.05 to 1.54) 1. The absolute risk increase was 0.6 percentage points over a median 1.9 years of follow-up. A 2010 meta-analysis in The Lancet by Sattar et al. Pooled 13 statin trials (N=91,140) and found a 9% increase in incident diabetes risk per statin (OR 1.09, 95% CI 1.02 to 1.17), with higher-intensity statins showing more signal 10. Rosuvastatin at 20 mg sits in the high-intensity category per ACC/AHA definitions 11.

What This Means for Practice

The net cardiovascular benefit of rosuvastatin dramatically outweighs the diabetes signal in patients with a 10-year ASCVD risk above 7.5%. Still, clinicians treating Hispanic patients with prediabetes or metabolic syndrome should document fasting glucose at baseline, recheck at 3 to 6 months after statin initiation, and counsel patients that any new hyperglycemia warrants lifestyle intensification, not statin discontinuation. The ACC/AHA 2019 Primary Prevention Guideline states explicitly: "For patients who develop diabetes while on statin therapy, statin therapy should be continued because the cardiovascular benefit outweighs the risk" 11.

Lipid Phenotype Differences That Affect Response Assessment

High Triglycerides and Low HDL as the Dominant Pattern

The most common dyslipidemia pattern in Hispanic adults is not isolated high LDL. It is a combination of elevated triglycerides (often 150 to 300 mg/dL), low HDL (frequently below 40 mg/dL in men, below 50 mg/dL in women), and near-normal or only modestly elevated LDL. This pattern reflects insulin resistance-driven hepatic overproduction of VLDL 12. Rosuvastatin does reduce triglycerides 20 to 28% and raises HDL 8 to 14%, making it a reasonable choice in this phenotype. However, the percent LDL reduction will appear smaller in absolute terms when baseline LDL is 110 mg/dL rather than 160 mg/dL, even if the relative reduction is identical.

Non-HDL Cholesterol as a Better Monitoring Target

Because rosuvastatin's cardiovascular benefit correlates with atherogenic particle burden rather than LDL alone, non-HDL cholesterol (total cholesterol minus HDL) is a more informative monitoring metric in patients with the high-TG/low-HDL phenotype. A 2022 ACC Expert Consensus Decision Pathway recommends non-HDL-C goals as secondary targets when fasting TG exceeds 200 mg/dL 13. Clinicians treating Hispanic patients with this phenotype should order a full fasting lipid panel and calculate non-HDL-C before and 6 to 8 weeks after any statin dose change.

Lipoprotein(a) Considerations

Lipoprotein(a) concentrations are not substantially affected by statins 14. In some studies, high-intensity statin therapy modestly raises Lp(a) by 10 to 25%. Hispanic populations have intermediate Lp(a) levels compared with Black (higher) and East Asian (lower) populations 15. Patients with unexpectedly high residual cardiovascular risk despite adequate LDL reduction should have Lp(a) measured, as this guides decisions about add-on therapies rather than statin dose increases.

Dosing Rosuvastatin in Hispanic and Latino Patients

Standard Dosing Range

The FDA-approved dosing range for rosuvastatin is 5 to 40 mg once daily. The FDA label specifically states that 5 mg/day is the recommended starting dose for patients of Asian ancestry due to pharmacokinetic data showing approximately two-fold higher AUC in Asian populations compared with Caucasians 16. No comparable FDA label modification exists for Hispanic or Latino patients.

Should Hispanic Patients Start at 5 mg?

The pharmacogenomic data reviewed above suggests a small but real subset of Hispanic patients, particularly those carrying SLCO1B1 c.521C and/or ABCG2 c.421A alleles, may have drug exposures that approach those seen in Asian ancestry patients. Blanket dose reduction for all Hispanic patients is not supported by current evidence. A targeted approach makes more sense: consider starting at 10 mg rather than 20 mg in Hispanic patients who also have multiple metabolic syndrome features, are taking interacting medications (cyclosporine, certain HIV antiretrovirals), or report a prior statin myopathy. Uptitrate at 6 to 8 weeks based on LDL-C response and tolerability.

Dose Ceiling for Myopathy Risk

Rosuvastatin 40 mg carries a higher myopathy risk than lower doses, and the FDA restricts 40 mg to patients who have not achieved adequate LDL response on 20 mg 16. Hispanic patients who are SLCO1B1 or ABCG2 variant carriers should have creatine kinase checked if they report new-onset myalgia at any dose. A single episode of unexplained CK elevation above 10 times the upper limit of normal warrants immediate statin discontinuation pending evaluation 17.

Pharmacogenomic Testing in Clinical Practice

Pharmacogenomic testing for SLCO1B1 and ABCG2 is available through commercial laboratories at costs ranging from $100 to $300, not yet uniformly covered by insurance. The Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for statins and SLCO1B1, published in Clinical Pharmacology and Therapeutics, provides actionable prescribing recommendations based on test results 18. For a Hispanic patient with prior statin intolerance or with a family history of statin myopathy, ordering a SLCO1B1/ABCG2 panel before selecting rosuvastatin 20 mg or 40 mg is a reasonable and increasingly affordable step.

Cardiovascular Outcomes Data: What the Hispanic Subgroups Actually Show

JUPITER Hispanic Subgroup

JUPITER enrolled participants across multiple countries and U.S. Sites. The Hispanic and Latino subgroup numbered approximately 1,600 participants across both arms. Published subgroup analyses show point estimates for major adverse cardiovascular event reduction consistent with the overall trial finding of HR 0.56 1. Subgroup analyses in large trials are typically underpowered to detect heterogeneity of effect by ethnicity; the confidence intervals for ethnic subgroups are wide. No statistically significant interaction between Hispanic ethnicity and rosuvastatin benefit was detected in JUPITER.

PREDIMED and Mediterranean Diet Context

While not a rosuvastatin trial, PREDIMED (N=7,447) demonstrated that a Mediterranean dietary intervention reduced major cardiovascular events by 30% in a high-risk Spanish-language population 19. Combining dietary modification with rosuvastatin therapy in Hispanic patients with metabolic syndrome may produce additive ASCVD risk reduction beyond what either intervention achieves alone. This combination is consistent with ACC/AHA lifestyle-plus-pharmacotherapy recommendations.

Real-World Adherence Data

A 2017 analysis in Circulation: Cardiovascular Quality and Outcomes examined statin adherence by race and ethnicity in a Medicare population (N=29,479) and found Hispanic patients had a medication possession ratio approximately 4 to 6 percentage points lower than non-Hispanic White patients at 12 months 20. Lower adherence, rather than pharmacokinetic differences, may account for a meaningful share of observed outcome disparities. Language-concordant counseling and simplified once-daily dosing schedules (rosuvastatin has a long half-life of approximately 19 hours, so timing flexibility is high) can address adherence gaps.

Drug Interactions Relevant to Hispanic Patient Populations

HIV Antiretroviral Therapy

HIV prevalence is disproportionately high in certain Hispanic communities. Several HIV antiretrovirals inhibit OATP1B1 or BCRP transporters and raise rosuvastatin AUC significantly. Lopinavir/ritonavir raises rosuvastatin AUC approximately 2.1-fold; atazanavir/ritonavir raises it approximately 1.6-fold 16. The FDA label recommends limiting rosuvastatin to 10 mg/day in patients taking lopinavir/ritonavir. Clinicians treating HIV-positive Hispanic patients with dyslipidemia should review the full antiretroviral regimen before prescribing.

Antacid Use and Absorption

Aluminum and magnesium hydroxide antacids reduce rosuvastatin AUC by approximately 54% when taken simultaneously 16. Patients should separate rosuvastatin from antacid use by at least 2 hours. High use of over-the-counter antacids is common in patients with metabolic syndrome and GERD, both of which are prevalent in Hispanic adults.

Practical Clinical Checklist for Prescribing Rosuvastatin in Hispanic Patients

Before Starting

• Calculate 10-year ASCVD risk using the Pooled Cohort Equations; note that some analyses suggest the PCE may underestimate risk in certain Hispanic subpopulations 21.
• Obtain fasting lipid panel, fasting glucose or HbA1c, CK, and hepatic function panel.
• Review full medication list for OATP1B1/BCRP inhibitors (antiretrovirals, cyclosporine, gemfibrozil).
• Ask about prior statin intolerance; if present, consider pharmacogenomic testing.

Starting Dose Selection

• No prior statin use, no interacting drugs, no metabolic syndrome: rosuvastatin 10 to 20 mg/day is appropriate.
• Metabolic syndrome plus prediabetes or multiple drug interactions: start at 10 mg/day, reassess at 6 weeks.
• Prior myopathy on another statin: check CK at baseline, start at 5 to 10 mg/day, monitor closely.

Monitoring at 6 to 8 Weeks

• Fasting lipid panel: target LDL-C reduction of at least 30 to 50% from baseline for moderate-intensity, at least 50% for high-intensity therapy 11.
• Fasting glucose or HbA1c in patients with prediabetes or metabolic syndrome.
• Ask about myalgia; check CK only if symptomatic.
• Reassess adherence barriers and consider Spanish-language patient education materials.